Int J Immunopathol Pharmacol . A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies

[tetano]

Int J Immunopathol Pharmacol


. Jan-Dec 2021;35:20587384211050199.
doi: 10.1177/20587384211050199.
A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies


Gabriela Athziri Sánchez-Zuno ¹ , Mónica Guadalupe Matuz-Flores ¹ , Guillermo González-Estevez ¹ , Ferdinando Nicoletti ² , Francisco Javier Turrubiates-Hernández ¹ , Katia Mangano ² , José Francisco Muñoz-Valle ¹



Affiliations

• PMID: 34632844
• DOI: 10.1177/20587384211050199

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented global public health emergency with economic and social consequences. One of the main concerns in the development of vaccines is the antibody-dependent enhancement phenomenon, better known as ADE. In this review, we provide an overview of SARS-CoV-2 infection as well as the immune response generated by the host. On the bases of this principle, we also describe what is known about the ADE phenomenon in various viral infections and its possible role as a limiting factor in the development of new vaccines and therapeutic strategies.

Keywords: ADE; COVID-19; SARS-CoV-2; antibody-dependent enhancement; vaccine.